BR0206917A - Uso de antagonistas de mglur5 para o tratamento de condições prurìticas - Google Patents

Uso de antagonistas de mglur5 para o tratamento de condições prurìticas

Info

Publication number
BR0206917A
BR0206917A BR0206917-2A BR0206917A BR0206917A BR 0206917 A BR0206917 A BR 0206917A BR 0206917 A BR0206917 A BR 0206917A BR 0206917 A BR0206917 A BR 0206917A
Authority
BR
Brazil
Prior art keywords
mglur5 antagonists
pruritic conditions
treat
treat pruritic
conditions
Prior art date
Application number
BR0206917-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Fabrizio Gasparini
Laszlo Urban
Josef Gottfried Meingassner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0206917A publication Critical patent/BR0206917A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR0206917-2A 2001-02-07 2002-02-06 Uso de antagonistas de mglur5 para o tratamento de condições prurìticas BR0206917A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0103045.1A GB0103045D0 (en) 2001-02-07 2001-02-07 Organic Compounds
PCT/EP2002/001250 WO2002062323A2 (en) 2001-02-07 2002-02-06 Use of mglur5 antagonists for the treatment of pruritic conditions

Publications (1)

Publication Number Publication Date
BR0206917A true BR0206917A (pt) 2004-02-03

Family

ID=9908300

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206917-2A BR0206917A (pt) 2001-02-07 2002-02-06 Uso de antagonistas de mglur5 para o tratamento de condições prurìticas

Country Status (13)

Country Link
US (2) US20040106582A1 (cg-RX-API-DMAC7.html)
EP (1) EP1359905B1 (cg-RX-API-DMAC7.html)
JP (2) JP2004517947A (cg-RX-API-DMAC7.html)
CN (1) CN1253151C (cg-RX-API-DMAC7.html)
AT (1) ATE333869T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002231777A1 (cg-RX-API-DMAC7.html)
BR (1) BR0206917A (cg-RX-API-DMAC7.html)
CA (1) CA2433409C (cg-RX-API-DMAC7.html)
DE (1) DE60213365T2 (cg-RX-API-DMAC7.html)
ES (1) ES2271229T3 (cg-RX-API-DMAC7.html)
GB (1) GB0103045D0 (cg-RX-API-DMAC7.html)
PT (1) PT1359905E (cg-RX-API-DMAC7.html)
WO (1) WO2002062323A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) * 2001-12-04 2002-01-23 Novartis Ag Organic compounds
GB0322612D0 (en) * 2003-09-26 2003-10-29 Novartis Ag Organic compounds
WO2005044266A1 (en) * 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes i
JP2007509935A (ja) * 2003-10-31 2007-04-19 アストラゼネカ アクチボラグ アルキンズii
WO2005044265A1 (en) * 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes iii
GB0503646D0 (en) * 2005-02-22 2005-03-30 Novartis Ag Organic compounds
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
JPWO2014034898A1 (ja) 2012-08-30 2016-08-08 日本新薬株式会社 ピリジン誘導体及び医薬
AU2016273751B2 (en) * 2015-06-03 2020-04-02 F. Hoffmann-La Roche Ag Ethynyl derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013744B1 (en) * 1989-12-29 1994-09-20 Allegran Inc Acetylenes disubstituted with a pyridinyl group and a substituted phenyl group having retinoid like activity
FR2719044B1 (fr) * 1994-04-26 1996-05-31 Cird Galderma Nouveaux composés bi-aromatiques acétylénés à groupement adamantyle, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5534641A (en) * 1994-12-29 1996-07-09 Allergan Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6774138B2 (en) * 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds

Also Published As

Publication number Publication date
PT1359905E (pt) 2006-11-30
DE60213365T2 (de) 2007-08-09
JP2004517947A (ja) 2004-06-17
ES2271229T3 (es) 2007-04-16
ATE333869T1 (de) 2006-08-15
CA2433409C (en) 2010-04-20
EP1359905B1 (en) 2006-07-26
CN1253151C (zh) 2006-04-26
US20040106582A1 (en) 2004-06-03
JP2012131829A (ja) 2012-07-12
CA2433409A1 (en) 2002-08-15
DE60213365D1 (de) 2006-09-07
US20070265279A1 (en) 2007-11-15
WO2002062323A3 (en) 2003-03-20
EP1359905A2 (en) 2003-11-12
AU2002231777A1 (en) 2002-08-19
GB0103045D0 (en) 2001-03-21
CN1535143A (zh) 2004-10-06
WO2002062323A2 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
DE69732868D1 (de) Mittel gegen Juckreiz
BR0016878A (pt) Inibidores tricìclicos de cinases protéicas
ATE554087T1 (de) Neue kinaseinhibitoren
CY1115124T1 (el) Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης
BRPI0506679A (pt) métodos de tratar osteoartrite com antagonistas de il-6
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
BR0212924A (pt) Inibidores de glicogênio sintase quinase-3 (gsk-3) para o tratamento de glaucoma
EA200300566A1 (ru) Применение cci-779 в качестве противоопухолевого средства
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
CL2007002389A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de obesidad, hirsutismo, hipertricosis y verrugas viricas.
DE50208918D1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
UA85394C2 (ru) Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
UY27606A1 (es) Inhibidores de la fosfarasa
ATE363531T1 (de) Claudin polypeptide
DK1373220T3 (da) Benzimidazoler, som er nyttige ved behandling af seksuel dysfunktion
TR200101756T2 (tr) Protein kinaz inhibitörleri olarak 4,5-pirazinoksindoller.
ATE411287T1 (de) Neue metallproteinaseinhibitoren
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE60329326D1 (de) Tace inhibitoren
BR0209883A (pt) Uso de inibidores da proteasoma para o tratamento de distúrbios do olho seco
TR200102448T2 (tr) COPD tedavisi için kontrollu salma formülasyonu.
AU2002231777A1 (en) Use of mglur5 antagonists for the treatment of pruritic conditions
ATE383874T1 (de) Perylenequinonen zur anwendung als sonosensitizer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.